DNAPrint Pharmaceuticals Completes the Development of an Analytical Method That Will Be Used for the Development of PT-401
DNAPrint Genomics, Inc. today announced that its subsidiary, DNAPrint Pharmaceuticals, Inc., has completed the development of the so-called "Western blot" method, an analytical procedure that identifies a protein according to its interaction with a specific antibody, a significant step in the development of its PT-401-based proprietary drug to treat anemia.
"The method ensures the identification of PT-401 and meets the requirements of the Food and Drug Administration for a successful Investigational New Drug filing," stated Hector J. Gomez, M.D., Ph.D., Chairman and Chief Medical Officer of DNAPrint Genomics and the Company's DNAPrint Pharmaceuticals subsidiary.
"The method assures that the development of PT-401 is moving forward," stated DNAPrint President and Chief Executive Officer Richard Gabriel. "We are making excellent progress in developing a successful treatment for anemia."
PT-401 is a "Super EPO," a more powerful form of Erythropoietin, a well-known drug used to treat anemia. PT-401 is a potential competitor in an EPO market that currently exceeds $10 billion and is rapidly growing.
DNAPrint Pharmaceuticals is developing "theranostic" genetic test/drug combinations designed to improve a drug's efficacy and reduce potential side effects. "Our genetic ancestry panel will help identify patient population groups most susceptible to the drug's potential toxic side effects," Mr. Gabriel said. "We believe our genetic ancestry technology offers a distinct, competitive advantage in its application to pharmaceutical development and theranostics. This is where Dr. Frudakis' and our scientific team's work on understanding genetic ancestry will really pay off."
DNAPrint Genomics is utilizing its EPOFusion(TM) model to simulate the cellular and molecular dynamics influenced by the administration of the Erythropoietin class of protein drugs in anemia treatments. EPOFusion(TM) models the interaction of PT-401 -- a novel 2-copy (dimer) form of Erythropoietin -- with the cells that trigger the production of new red blood cells. EPOFusion(TM) can be manipulated to test hundreds of conditions and variables by simulating what occurs in the whole blood cell production process. The EPOFusion(TM) model has already identified important differences between PT-401 and currently marketed drugs or drugs in development by other companies. This type of information may provide a competitive advantage and is critical for transparent regulatory filings and effective physician education upon FDA approval of a drug for clinical testing.
"The method ensures the identification of PT-401 and meets the requirements of the Food and Drug Administration for a successful Investigational New Drug filing," stated Hector J. Gomez, M.D., Ph.D., Chairman and Chief Medical Officer of DNAPrint Genomics and the Company's DNAPrint Pharmaceuticals subsidiary.
"The method assures that the development of PT-401 is moving forward," stated DNAPrint President and Chief Executive Officer Richard Gabriel. "We are making excellent progress in developing a successful treatment for anemia."
PT-401 is a "Super EPO," a more powerful form of Erythropoietin, a well-known drug used to treat anemia. PT-401 is a potential competitor in an EPO market that currently exceeds $10 billion and is rapidly growing.
DNAPrint Pharmaceuticals is developing "theranostic" genetic test/drug combinations designed to improve a drug's efficacy and reduce potential side effects. "Our genetic ancestry panel will help identify patient population groups most susceptible to the drug's potential toxic side effects," Mr. Gabriel said. "We believe our genetic ancestry technology offers a distinct, competitive advantage in its application to pharmaceutical development and theranostics. This is where Dr. Frudakis' and our scientific team's work on understanding genetic ancestry will really pay off."
DNAPrint Genomics is utilizing its EPOFusion(TM) model to simulate the cellular and molecular dynamics influenced by the administration of the Erythropoietin class of protein drugs in anemia treatments. EPOFusion(TM) models the interaction of PT-401 -- a novel 2-copy (dimer) form of Erythropoietin -- with the cells that trigger the production of new red blood cells. EPOFusion(TM) can be manipulated to test hundreds of conditions and variables by simulating what occurs in the whole blood cell production process. The EPOFusion(TM) model has already identified important differences between PT-401 and currently marketed drugs or drugs in development by other companies. This type of information may provide a competitive advantage and is critical for transparent regulatory filings and effective physician education upon FDA approval of a drug for clinical testing.
0 Comments:
Post a Comment
<< Home